Suzhou Basecare Medical Corporation Limited logo

Suzhou Basecare Medical Corporation Limited

2170.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$1.34

−HK$0.05 · -3.60%

Aug 24, 4:08 PM HKT

2170.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and manufacturing of genetic testing solutions specifically for assisted reproduction, alongside the distribution of related medical devices and instruments. Its extensive product line includes a range of genetic test kits for reproductive health. These comprise pre-implantation genetic tests such as PGT-A, designed to screen for chromosomal aneuploidies; PGT-M, which identifies single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits, used to detect chromosomal structural rearrangements often linked to recurrent miscarriages. Additionally, Basecare offers prenatal test kits (CNV kits) and postnatal test kits (WES kits). Complementing its genetic testing offerings, the company supplies various specialized medical equipment, including liquid nitrogen storage dewars, cryostorage systems, automated workstations, sperm quality analyzers, and next-generation sequencing (NGS) sequencers. Beyond manufacturing and sales, Basecare also provides marketing services and develops software for its medical devices and instruments. Its primary clientele consists of hospitals and reproductive clinics.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Bo Liang
Listed since
Feb 8, 2021
Employees
407

Market position

Day range

Current HK$1.34

52-week range

Current HK$1.34

Open
HK$1.30
Previous close
HK$1.39
Volume
391.5K
5.02× average
Average volume
78K
Average daily volume
Market cap
366.52M HKD
Beta
0.04
Market reference 1
50-day average
HK$1.3939
-3.87% below average
200-day average
HK$1.8074
-25.86% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
381.26M CNY
P/E (TTM)
-1.4×
P/B (TTM)
0.34×
P/S (TTM)
1.35×
EV / EBITDA
-2.28×
Earnings yield
-48.90%
Free cash flow yield
-53.26%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
52.99%
Operating margin
-91.77%
Net margin
-95.79%
Return on equity
-23.90%
Return on assets
-15.44%
Return on invested capital
-16.33%

Financial health

Debt / equity
0.37×
Current ratio
3.98×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends72%-3%-78%-153%Gross margin, FY2021: 47.67%Gross margin, FY2022: 42.25%Gross margin, FY2023: 43.92%Gross margin, FY2024: 45.54%Gross margin, FY2025: 52.99%Operating margin, FY2021: -116.02%Operating margin, FY2022: -89.51%Operating margin, FY2023: -93.14%Operating margin, FY2024: -77.22%Operating margin, FY2025: -91.77%Net margin, FY2021: -133.88%Net margin, FY2022: -87.41%Net margin, FY2023: -92.17%Net margin, FY2024: -79.25%Net margin, FY2025: -95.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.67%. Gross margin FY2022 42.25%. Gross margin FY2023 43.92%. Gross margin FY2024 45.54%. Gross margin FY2025 52.99%. Operating margin FY2021 -116.02%. Operating margin FY2022 -89.51%. Operating margin FY2023 -93.14%. Operating margin FY2024 -77.22%. Operating margin FY2025 -91.77%. Net margin FY2021 -133.88%. Net margin FY2022 -87.41%. Net margin FY2023 -92.17%. Net margin FY2024 -79.25%. Net margin FY2025 -95.79%.

Income trends

Revenue

233.27M CNY-22.01%

Operating income

−214.08M CNY+7.31%

Net income

−223.46M CNY+5.73%
Income trends across reported periods352.72M CNY138.27M CNY−76.19M CNY−290.64M CNYRevenue, FY2021: 107.3M CNYRevenue, FY2022: 140.9M CNYRevenue, FY2023: 207.98M CNYRevenue, FY2024: 299.11M CNYRevenue, FY2025: 233.27M CNYOperating income, FY2021: −124.49M CNYOperating income, FY2022: −126.12M CNYOperating income, FY2023: −193.71M CNYOperating income, FY2024: −230.97M CNYOperating income, FY2025: −214.08M CNYNet income, FY2021: −143.65M CNYNet income, FY2022: −123.16M CNYNet income, FY2023: −191.69M CNYNet income, FY2024: −237.03M CNYNet income, FY2025: −223.46M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 107.3M CNY. Revenue FY2022 140.9M CNY. Revenue FY2023 207.98M CNY. Revenue FY2024 299.11M CNY. Revenue FY2025 233.27M CNY. Operating income FY2021 −124.49M CNY. Operating income FY2022 −126.12M CNY. Operating income FY2023 −193.71M CNY. Operating income FY2024 −230.97M CNY. Operating income FY2025 −214.08M CNY. Net income FY2021 −143.65M CNY. Net income FY2022 −123.16M CNY. Net income FY2023 −191.69M CNY. Net income FY2024 −237.03M CNY. Net income FY2025 −223.46M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue233.27M CNY299.11M CNY207.98M CNY140.9M CNY107.3M CNY
Cost of goods sold109.66M CNY162.89M CNY116.63M CNY81.37M CNY56.15M CNY
Gross profit123.61M CNY136.22M CNY91.35M CNY59.53M CNY51.15M CNY
Research and development106.42M CNY135.26M CNY129.57M CNY119.77M CNY73.71M CNY
Selling, general, and administrative231.97M CNY276.39M CNY209.3M CNY161.5M CNY114.64M CNY
Operating expenses337.69M CNY367.19M CNY285.06M CNY185.65M CNY175.63M CNY
Interest income11.8M CNY25.27M CNY38.51M CNY23.62M CNY18.2M CNY
Interest expense13.12M CNY9.37M CNY2.61M CNY496K CNY1.26M CNY
Depreciation and amortization43.79M CNY14.49M CNY19.57M CNY8.39M CNY5.59M CNY
Operating income−214.08M CNY−230.97M CNY−193.71M CNY−126.12M CNY−124.49M CNY
Net income−223.46M CNY−237.03M CNY−191.69M CNY−123.16M CNY−143.65M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.44

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.1-0.27-0.44-0.6Q3 '22Q1 '23Q3 '23Q1 '24Q1 '24Q3 '24Q1 '25Q3 '25
Q3 2022, reported Aug 29, 2022: actual -0.117, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual -0.126, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual -0.216, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 1, 2024: actual -0.564, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual -0.238, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual -0.43, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual -0.235, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual -0.438, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates543.57M376.21M208.86M41.5MQ1 '23MissQ3 '23No estimateQ1 '24MissQ1 '24MissQ3 '24No estimateQ1 '25No estimateQ3 '25No estimateQ3 '26Estimate
Q1 2023, reported Mar 30, 2023: actual 48.82M HKD, estimate 299.42M HKD, surprise -83.69%, Miss. Q3 2023, reported Aug 30, 2023: actual 92.45M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 1, 2024: actual 132.57M HKD, estimate 506.92M HKD, surprise -73.85%, Miss. Q1 2024, reported Mar 28, 2024: actual 67.48M HKD, estimate 397.05M HKD, surprise -83.01%, Miss. Q3 2024, reported Aug 29, 2024: actual 134.02M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 54.07M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 29, 2025: actual 111.05M HKD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 28, 2026: actual —, estimate 85.25M HKD, surprise —, Comparison unavailable.

Continue in GoAI

Research 2170.HK

research.disclaimer